Answers are grounded in this paper and cite their sources.
Literature review examines ischemic risk and antithrombotic therapies in multifocal atherosclerosis, highlighting the critical need to prevent major cardiovascular events.
In patients with atherosclerotic lesions of two or more systems or multifocal atherosclerosis (MFA), the risks of ischemic events are extremely high. MFA leads not only to cardiovascular outcomes, but also to a decrease in the patient’s quality of life, life expectancy, and in most cases to disability. The prevalence of this pathology and the importance of preventing adverse outcomes are often underestimated. This literature review examines the problem of MFA in the context of key studies on the prevalence, course of multivessel disease and the reduction of the risk of cardiovascular events in this group of patients, with an emphasis on antiplatelet and anticoagulant therapy.
No takes yet. Share an insight, caveat, or question.
Arutyunov et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: